Latest News - Clearside Biomedical

Thursday, February 16, 2017 | Clinical Trials, Clearside Biomedical

Clearside Biomedical Announces First Patient Randomized in Phase 3 Clinical Trial of Zuprata Used Together With Eylea in Subjects With RVO

Clearside Biomedical announced the enrollment of the first patient in a phase 3 clinical trial (SAPPHIRE) of Zuprata, its proprietary suspension formulation of the corticosteroid triamcinolone acetoni…

Read the full story

Monday, October 10, 2016 | Clinical Trials, Clearside Biomedical

Clearside Biomedical to Report Clinical Trial Results at 2016 Retina Subspecialty Day Meeting at the American Academy of Ophthalmology Meeting

Clearside Biomedical announced that results from two clinical trials, including the TANZANITE trial, “Safety and Efficacy of Suprachoroidal Triamcinolone Acetonide Concomitant with Intravitreal …

Read the full story

Tuesday, July 26, 2016 | Clinical Trials, Clearside Biomedical

Clearside Biomedical Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with RVO

Clearside Biomedical reported additional topline data from its phase 2 clinical trial (TANZANITE). The 46-patient trial, with topline results originally reported in April 2016, evaluated the treatment…

Read the full story

Thursday, June 02, 2016 | Earnings & Financials, Clearside Biomedical

Clearside Biomedical Announces Pricing of Initial Public Offering

Clearside Biomedical announced the pricing of its initial public offering of 7,200,000 shares of its common stock at a public offering price of $7.00 per share, according to a company news relea…

Read the full story

Thursday, April 28, 2016 | Conferences, Clearside Biomedical

Clearside Biomedical to Present Data on Suprachoroidal Drug Administration at 2016 ARVO Meeting

Clearside Biomedical announced four poster presentations associated with suprachoroidal drug administration will be presented at the 2016 Annual Meeting of the Association for Research in Vision and O…

Read the full story

Tuesday, April 26, 2016 | Clinical Trials, Clearside Biomedical

Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients with Macular Edema Associated with RVO

Clearside Biomedical announced that its phase 2 clinical trial evaluating concomitant administration of suprachoroidal Zuprata, Clearside’s proprietary form of triamcinolone acetonide, together …

Read the full story

Tuesday, January 05, 2016 | Clinical Trials, Clearside Biomedical

Clearside Biomedical Announces Positive Topline Data from Phase 2 Clinical Trial for the Treatment of Macular Edema Associated with Non-Infectious Uveitis

Clearside Biomedical announced positive results from the company’s phase 2 clinical trial of CLS-TA, Clearside’s proprietary form of triamcinolone acetonide, using suprachoroidal space (SC…

Read the full story

Monday, December 14, 2015 | Clinical Trials, Clearside Biomedical

Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space (SCS) Drug Administration

Clearside Biomedical announced completion of enrollment in the company’s phase 2 clinical trial (Tanzanite) for the treatment of macular edema associated with retinal vein occlusion (RVO), accor…

Read the full story

Monday, December 07, 2015 | Clinical Trials, Clearside Biomedical

Clearside Biomedical Enrolls First Patient in Phase 3 Clinical Trial of CLS-TA Using Suprachoroidal Drug Administration

Clearside Biomedical announced that the first patient was enrolled in Clearside’s phase 3 clinical trial, Peachtree, of CLS-TA, Clearside’s proprietary form of triamcinolone acetonid…

Read the full story

Monday, October 12, 2015 | Clinical Trials, Clearside Biomedical

Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA Using Suprachoroidal Space

Clearside Biomedical announced completion of enrollment in the company’s phase 2 clinical trial (Dogwood) of CLS-TA, Clearside’s proprietary form of triamcinolone acetonide, using su…

Read the full story

Tuesday, June 16, 2015 | Clinical Trials, Clearside Biomedical

Clearside Biomedical Announces Favorable End-of-Phase 2 Review with the FDA

Clearside Biomedical announced a favorable end-of-phase 2 review with the FDA on its lead drug triamcinolone acetonide (TA) administered via injection into the suprachoroidal space for the treatment o…

Read the full story

Monday, May 04, 2015 | Partnerships, Clearside Biomedical , Santen

Clearside Biomedical and Santen Announce Research Collaboration in Glaucoma

Clearside Biomedical and Santen announced the expansion of their research collaboration to include the field of glaucoma. The two companies have been working together since January 2013 to develop dru…

Read the full story

Wednesday, April 29, 2015 | Acquisitions/Mergers, Clearside Biomedical

Spark Therapeutics and Clearside Biomedical Announce Exclusive Option to License Technology for Potentially Differentiated Delivery of Gene Therapy to the Eye

Spark Therapeutics and Clearside Biomedical announced that they have entered into an option agreement under which Spark acquired exclusive rights to license Clearside’s microinjector technology …

Read the full story

Wednesday, April 22, 2015 | Acquisitions/Mergers, Clearside Biomedical , iScience

Clearside Biomedical Announces Purchase of iScience Patent Portfolio for Suprachoroidal Space Drug Delivery

Clearside Biomedical announced the purchase and acquisition of iScience Interventional Corporation’s patent portfolio, covering drug delivery to the suprachoroidal space (SCS), according t…

Read the full story

Monday, March 16, 2015 | Clinical Trials, Clearside Biomedical

Clearside Biomedical Reports Efficacy and Safety Results in Noninfectious Uveitis Using a Single Suprachoroidal Injection of Triamcinolone Acetonide

Clearside Biomedical announced the efficacy and safety results from the company’s recently completed 6-month phase 1/2 clinical trial, according to a company news release. In the trial, eight pa…

Read the full story
Load More